Four-Fraction Radiation Therapy for Macroscopic Soft Tissue Sarcomas in 16 Dogs

2008 ◽  
Vol 44 (3) ◽  
pp. 100-108 ◽  
Author(s):  
Jessica Lawrence ◽  
Lisa Forrest ◽  
William Adams ◽  
David Vail ◽  
Douglas Thamm
Keyword(s):  
Radiation Therapy ◽  
Retrospective Study ◽  
Soft Tissue ◽  
Overall Response Rate ◽  
Response Rate ◽  
Soft Tissue Sarcomas ◽  
Complete Response ◽  
Time To Progression ◽  
Fractionated Radiation Therapy ◽  
Fractionated Radiation

A retrospective study of 16 dogs with macroscopic soft tissue sarcomas was performed to evaluate response to a four-fraction radiotherapy protocol (prescribed dose of 32 Gy). Radiation was well tolerated with minimal side effects. The overall response rate was 50%, with seven partial responses and one complete response. The median time to progression was 155 days, and the median survival time was 309 days. Coarsely fractionated radiation therapy may be a reasonable palliative option for dogs with unresectable soft tissue sarcomas, although the response is relatively short-lived.

scholarly journals Fractionated Radiation Therapy for Large and Giant Cavernous Sinus Hemangioma: A Retrospective Study

2020 ◽  
Vol 11 ◽  
Author(s):  
Zengfeng Xin ◽  
Yihan Yao ◽  
Guodi Chen ◽  
Liancong Wang ◽  
Meibao Shu ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Retrospective Study ◽  
Cavernous Sinus ◽  
Fractionated Radiation Therapy ◽  
Fractionated Radiation

Radiation therapy in the treatment of canine and feline thymomas: a retrospective study (1985-1999)

2001 ◽  
Vol 37 (5) ◽  
pp. 489-496 ◽  
Author(s):  
AN Smith ◽  
JC Wright ◽  
Brawner WRJr ◽  
SM LaRue ◽  
L Fineman ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Retrospective Study ◽  
Survival Time ◽  
Median Survival ◽  
Stable Disease ◽  
Tumor Size ◽  
Median Survival Time ◽  
Overall Response Rate ◽  
Response Rate ◽  
Clinical Signs

A retrospective study was performed of 17 dogs and seven cats with various stages of thymoma treated with radiation alone or as an adjunctive therapy. Analysis revealed an overall response rate of 75% (15/20 evaluable cases). Partial (i.e., >50% reduction in tumor size) and complete (i.e., no detectable tumor) responses were included. Complete responses were rare (4/20). Three of five animals with stable disease (i.e., <50% change in tumor size) had improvements in clinical signs, despite lack of measurable response. A median survival time of 248 days (range, 93 to 1,657+ days) was achieved in dogs, and a median survival time of 720 days (range, 485 to 1,825+ days) was achieved in cats. Radiation therapy appears to be useful in the management of invasive thymomas in dogs and cats.

High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies--dose-response and schedule dependence.

1997 ◽  
Vol 15 (6) ◽  
pp. 2378-2384 ◽  
Author(s):  
S R Patel ◽  
S Vadhan-Raj ◽  
N Papadopolous ◽  
C Plager ◽  
M A Burgess ◽  
...  
Keyword(s):  
Pilot Study ◽  
Soft Tissue ◽  
Continuous Infusion ◽  
Phase Ii ◽  
Dose Response ◽  
Overall Response Rate ◽  
Response Rate ◽  
Soft Tissue Sarcomas ◽  
High Dose ◽  
Grade 3

PURPOSE To evaluate the efficacy and feasibility of high-dose ifosfamide (HDI) at a total dose of 14 g/m2 per cycle with mesna in combination with granulocyte colony-stimulating factor (G-CSF) in adult patients with sarcomas. PATIENTS AND METHODS Between July 1991 and February 1994, 74 patients with sarcomas (37 bone and 37 soft tissue) were treated on two simultaneous phase II studies that evaluated HDI given as a continuous infusion over 74 hours. G-CSF was started on day 5 at 5 microg/kg/d until recovery of granulocyte count. Additionally, between March 1993 and March 1994, 15 similar patients with previously treated bone or soft tissue sarcomas were treated on a pilot study in which the same total dose of ifosfamide was administered by a bolus schedule, along with mesna and G-CSF. Patients were treated until maximal response, and where possible, surgical resection of gross disease was performed. RESULTS Seventy-two patients from the phase II study using continuous infusion are assessable for response. Four complete responses (CRs) and 17 partial responses (PRs) were noted, for an overall response rate of 29% (95% confidence interval [CI], 19% to 39%). The response rate was 40% (95% CI, 24% to 56%) for bone sarcomas and 19% (95% CI, 6% to 32%) for soft tissue sarcomas. Fourteen patients from the pilot study that used a bolus schedule are assessable for response. One CR and seven PRs were noted, for an overall response rate of 57% (95% CI, 31% to 83%) and a response rate of 45% for soft tissue sarcomas. Two patients developed grade 3 to 4 renal toxicity, three developed grade 3 CNS toxicity, one had possible grade 3 cardiac toxicity, and two developed severe painful peripheral neuropathy. There were no treatment-related deaths. CONCLUSION HDI at 14 g/m2 with mesna and G-CSF is an active salvage regimen for patients with bone and soft tissue sarcomas. There is a definite positive dose-response curve, and bolus administration appears to be more active than continuous infusion.

scholarly journals Outcomes of First-Line Chemotherapy in Patients with Advanced or Metastatic Leiomyosarcoma of Uterine and Non-Uterine Origin

Sarcoma ◽  
2009 ◽  
Vol 2009 ◽  
pp. 1-6 ◽  
Author(s):  
A. W. Oosten ◽  
C. Seynaeve ◽  
P. I. M. Schmitz ◽  
M. A. den Bakker ◽  
J. Verweij ◽  
...  
Keyword(s):  
Overall Survival ◽  
Retrospective Study ◽  
Gastrointestinal Stromal Tumors ◽  
Overall Response Rate ◽  
Response Rate ◽  
Soft Tissue Sarcomas ◽  
Histological Subtype ◽  
First Line ◽  
Stromal Tumors ◽  
Line Chemotherapy

Although leiomyosarcomas (LMSs) form the largest subgroup of soft tissue sarcomas (STSs), the efficacy of chemotherapy in this group is largely unclear, partly because older studies are contaminated with gastrointestinal stromal tumors (GISTs). In this retrospective study we investigated the outcome of first line chemotherapy in 65 patients with unresectable or metastatic LMS. The overall response rate (ORR) was 18%; and the median progression-free (PFS) and overall survival (OS) were 3.8 and 9.7 months respectively. No statistically significant differences in outcomes for uterine and non-uterine LMS were found. In non-uterine LMS, however, the PFS and OS seemed to be longer for females than for males, potentially negatively affecting outcomes in this group. If our observations are confirmed in other series, they would suggest that studies performed in STS patients should not only stratify for histological subtype but also for uterine versus non-uterine LMS and for gender.

Cisplatin, doxorubicin, and 5-fluorouracil chemotherapy for salivary gland malignancies: a pilot study of the Northern California Oncology Group.

1987 ◽  
Vol 5 (6) ◽  
pp. 951-955 ◽  
Author(s):  
A P Venook ◽  
A Tseng ◽  
F J Meyers ◽  
I Silverberg ◽  
R Boles ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Salivary Gland ◽  
Overall Response Rate ◽  
Response Rate ◽  
Recurrent Disease ◽  
Response Duration ◽  
Complete Response ◽  
Outpatient Setting ◽  
Salivary Gland Cancer ◽  
Oncology Group

Seventeen patients with advanced or recurrent salivary gland cancer were treated with cisplatin, doxorubicin, and 5-fluorouracil combination chemotherapy (PAF). Two patients achieved a complete response and four patients achieved a partial response, for an overall response rate of 35%. Six of the nine patients who received PAF in the neoadjuvant setting did not respond and proceeded to surgery and/or radiation therapy. No difference in response rate was found between those patients treated for recurrent disease v those treated with neoadjuvant chemotherapy. All three patients with adenocarcinoma responded. The response duration in patients with metastatic or recurrent disease ranged from 6 to 15 months. The PAF regimen was delivered primarily in the outpatient setting and was associated with acceptable toxicity. PAF demonstrates activity in salivary gland malignancies, and further evaluation of this combination seems warranted.

scholarly journals The Radiation Response of Sarcomas by Histologic Subtypes: A Review With Special Emphasis Given to Results Achieved With Razoxane

Sarcoma ◽  
2006 ◽  
Vol 2006 ◽  
pp. 1-9 ◽  
Author(s):  
Walter Rhomberg
Keyword(s):  
Radiation Therapy ◽  
Soft Tissue ◽  
Response Rate ◽  
Radiation Treatment ◽  
Soft Tissue Sarcomas ◽  
Radiation Response ◽  
Review Of The Literature ◽  
Adult Type ◽  
High Let

Purpose. Relatively few results are available in the literature about the radiation response of unresectable sarcomas in relation to their histology. Therefore, an attempt was made to summarize the present situation. Materials and methods. This report is based on a review of the literature and the author's own experience. Adult-type soft tissue sarcomas, chondrosarcomas, and chordomas were analyzed. Radioresponse was mainly associated with the degree of tumor shrinkage, that is, objective responses. Histopathologic responses, that is, the degree of necrosis, are only discussed in relation to radiation treatment reports of soft tissue sarcomas as a group. Results. Radiation therapy alone leads to major responses in about 50% of lipo-, fibro-, leiomyo-, or chondrosarcomas. The response rate is less than 50% in malignant fibrous histiocytomas, synovial, neurogenic, and other rare soft tissue sarcomas. The response rates may increase up to 75% through the addition of radiosensitizers such as halogenated pyrimidines or razoxane, or by the use of high-LET irradiation. Angiosarcomas become clearly more responsive if biologicals, angiomodulating, and/or tubulin affinic substances are given together with radiation therapy. Razoxane is able to increase the duration and quality of responses even in difficult-to-treat tumors like chondrosarcomas or chordomas. Conclusions. The available data demonstrate that the radioresponsiveness of sarcomas is very variable and dependent on histology, kind of radiation, and various concomitantly given drugs. The rate of complete sustained remissions by radiation therapy alone or in combination with drugs is still far from satisfactory although progress has been made through the use of sensitizing agents.

scholarly journals Efficacy of Phosphatidylinositol-3 Kinase Inhibitors in a Primary Mouse Model of Undifferentiated Pleomorphic Sarcoma

Sarcoma ◽  
2012 ◽  
Vol 2012 ◽  
pp. 1-8 ◽  
Author(s):  
Suzy Kim ◽  
Rebecca D. Dodd ◽  
Jeffrey K. Mito ◽  
Yan Ma ◽  
Yongbaek Kim ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Partial Response ◽  
Mouse Model ◽  
Kinase Inhibitors ◽  
Response Rate ◽  
Complete Response Rate ◽  
Soft Tissue Sarcomas ◽  
Complete Response ◽  
Pi3k Pathway ◽  
Primary Mouse

Recent advances in sarcoma genomics have identified novel mutations in the PI3K pathway in human sarcomas. Here, we use a mouse model of primary soft-tissue sarcoma for preclinical testing of doxorubicin and inhibitors of the PI3K pathway: BKM120 (PI3K inhibitor) and BEZ235 (a dual PI3K/mTOR inhibitor). Doxorubicin-treated tumors (n=15) showed a partial response rate of 6.6%, just as the majority of human sarcomas do not respond to doxorubicin. Treatment with BKM120 elicited a partial response in 50% of tumors (n=10), which was also seen in combination with doxorubicin (n=10). Additionally, BKM120 treatment produced a robust delay in tumor growth kinetics. BEZ235-treated tumors (n=9) showed a complete response rate of 11.1%. Combining BEZ235 with doxorubicin (n=10) increased the complete response rate to 50% (P=0.035). These studies demonstrate that PI3K pathway inhibition is a viable and attractive target for soft-tissue sarcomas.

Response to radiation therapy in solitary fibrous tumor/hemangiopericytoma.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 10065-10065
Author(s):  
Giacomo Baldi ◽  
Michela Libertini ◽  
Silvia Stacchiotti ◽  
Andrea Marrari ◽  
Elena Palassini ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Soft Tissue ◽  
Abdominal Wall ◽  
Progressive Disease ◽  
Overall Response Rate ◽  
Response Rate ◽  
Concomitant Chemotherapy ◽  
Best Response ◽  
Fibrous Tumor ◽  
Palliative Setting

10065 Background: To reporton the activity of radiotherapy (RT) in a retrospective series of solitary fibrous tumors (SFT)/hemagiopericytoma (HCP), a rare soft tissue sarcoma subtype whose sensitivity to RT is poorly known. Methods: We retrospectively reviewed all patients with a diagnosis of SFT/HCP whom we saw from 2005 to 2011, focusing on cases treated with RT in neoadjuvant, adjuvant, exclusive, palliative settings. Patients who received concomitant chemotherapy were excluded. We confirmed diagnosis by review in all cases. We evaluated the overall response rate (RR) by RECIST. Results: Nineteen patients were identified (males = 9, females = 10; median age = 61 years, range 39-85; site of primary= 6 meninges, 4 pleura, 3 pelvis, 3 retroperitoneum, 2 limbs, 1 abdominal wall; site of RT= 5 bone and soft tissue, 5 pelvis, 3 soft tissue, 2 meninges, 2 retroperitoneum, 1 abdominal wall, 1 pleura; reason for RT= 3 neoadjuvant, 2 adjuvant, 2 exclusive and 12 palliative setting). Median RT dose was 42 Gy (range 12-60). Seventeen of 19 pts are evaluable for response (2 adjuvant). The RR was: 29% (4 pts) partial response, 65% (12 pts) stable disease (SD), 6% (1 pt) progressive disease (PD). All patients treated with neoadjuvant RT had a RECIST SD as best response to pre-operative treatment with evidence of pathologic response in 2 of 3 cases. Conclusions: Contrary to what is widely thought,this retrospective analysis suggests that SFT/HCP is sensitive to radiation therapy. Prospective studies are needed.

Sign in / Sign up

Export Citation Format

Share Document